Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31525 | 0.87 | HPGD (0.77) | HPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL3923867 | 0.83 | HPGD (0.70) | HPGDFGFR3KDRNPC1RAB9A | |
| SCHEMBL3925188 | 0.82 | HPGD (0.69) | HPGDFGFR3KDRNPC1RAB9A | |
| SCHEMBL3925199 | 0.82 | HPGD (0.69) | HPGDFGFR3KDRNPC1RAB9A | |
| SCHEMBL3925191 | 0.81 | HPGD (0.67) | HPGDFGFR3KDR | |
| SCHEMBL24329732 | 0.79 | HPGD (0.65) | HPGDFGFR3KDR | |
| SCHEMBL23675137 | 0.78 | HPGD (0.64) | HPGDNPC1RAB9ATP53ALDH1A1 | |
| SCHEMBL556989 | 0.76 | FGFR3 (0.71) | FGFR3KDR | |
| SCHEMBL16331487 | 0.75 | MKNK1 (0.70) | HPGD | |
| SCHEMBL563885 | 0.74 | HPGD (0.58) | HPGDFGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335043-B | PGDH inhibitors and methods of making and using the same | 迈欧伏特治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4093385-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Myoforte Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885FGFR3 4025/4885KDR 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.